Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8 + T cells

European Journal of Immunology

Volumn 42, Issue 3, 2012, Pages 662-671

  Kaiser, Andrew D ^a   Schuster, Kerstin ^a,b   Gadiot, Jules ^a   Borkner, Lisa ^b   Daebritz, Henry ^c   Schmitt, Clemens ^c   Andreesen, Reinhard ^b   Blank, Christian ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

PD 1; PD L1; T cells; Tumor microenvironment

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELL STRESS; CELL SURFACE; CONTROLLED STUDY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD274; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC;

EID: 84859495695     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201141931     Document Type: Article

References (39)

1. Gajewski, T. F., Meng, Y. and Harlin, H., Immune suppression in the tumor microenvironment. J. Immunother. 2006. 29: 233-240.
2. Vesely, M. D., Kershaw, M. H., Schreiber, R. D. and Smyth, M. J., Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011. 29: 235-271.
3. Blank, C. and Mackensen, A., Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol. Immunother. 2007. 56: 739-745.
4. + T-cell tolerance that is reversible and requires CD4-CD8- cells and interferon gamma. J. Exp. Med. 1997. 186: 71-81.
5. De Mattia, F., Chomez, S., Van Laethem, F., Moulin, V., Urbain, J., Moser, M., Leo, O. and Andris, F., Antigen-experienced T cells undergo a transient phase of unresponsiveness following optimal stimulation. J. Immunol. 1999. 163: 5929-5936.
6. Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E. and Rosenberg, S. A., Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009. 114: 1537-1544.
7. + T-cell anergy in vivo. J. Immunol. 2009. 182: 6682-6689.
8. Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J. et al., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000. 192: 1027-1034.
9. + T cells. J. Clin. Invest. 2005. 115: 1616-1626.
10. Sharpe, A. H., Wherry, E. J., Ahmed, R. and Freeman, G. J., The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 2007. 8: 239-245.
11. Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y. et al., PD-L2 is a second ligand for PD-1 and inhibits T-cell activation. Nat. Immunol. 2001. 2: 261-268.
12. Keir, M. E., Butte, M. J., Freeman, G. J. and Sharpe, A. H., PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008. 26: 677-704.
13. Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S. et al., Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006. 66: 3381-3385.
14. Ghebeh, H., Mohammed, S., Al-Omair, A., Qattan, A., Lehe, C., Al-Qudaihi, G., Elkum, N. et al., The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006. 8: 190-198.
15. Gadiot, J., Hooijkaas, A. I., Kaiser, A. D., van Tinteren, H., van Boven, H. and Blank, C., Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011. 117: 2192-2201.
16. Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T. and Tokura, Y., Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010. 116: 1757-1766.
17. Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J. and Ahmed, R., Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006. 439: 682-687.
18. + T cells. Cancer Res. 2004. 64: 1140-1145.
19. + T lymphocytes in the P815 tumor system in vitro. J. Immunol. 1996. 156: 465-472.
20. Gajewski, T. F., Markiewicz, M. A. and Uyttenhove, C., The p815 mastocytoma tumor model. Curr. Protoc. Immunol. 2001. Chapter 20: Unit 20 24.
21. Kranz, D. M., Tonegawa, S. and Eisen, H. N., Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 1984. 81: 7922-7926.
22. Freeman, G. J., Wherry, E. J., Ahmed, R. and Sharpe, A. H., Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 2006. 203: 2223-2227.
23. Wherry, E. J., T-cell exhaustion. Nat. Immunol. 2011. 12: 492-499.
24. Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C. et al., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002. 8: 793-800.
25. Lee, S., Dorken, B. and Schmitt, C. A., Extracorporeal photopheresis in graft-versus-host disease: ultraviolet radiation mediates T-cell senescence in vivo. Transplantation 2004. 78: 484-485.
26. Spiotto, M. T., Rowley, D. A. and Schreiber, H., Bystander elimination of antigen loss variants in established tumors. Nat. Med. 2004. 10: 294-298.
27. Spiotto, M. T., Yu, P., Rowley, D. A., Nishimura, M. I., Meredith, S. C., Gajewski, T. F., Fu, Y. X. and Schreiber, H., Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002. 17: 737-747.
28. Blank, C., Brown, I., Marks, R., Nishimura, H., Honjo, T. and Gajewski, T. F., Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J. Immunol. 2003. 171: 4574-4581.
29. Seliger, B., Wollscheid, U., Momburg, F., Blankenstein, T. and Huber, C., Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 2001. 61: 1095-1099.
30. + T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 2006. 211: 214-224.
31. Miescher, S., Whiteside, T. L., Carrel, S. and von Fliedner, V., Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol. 1986. 136: 1899-1907.
32. Dong, H. and Chen, L., B7-H1 pathway and its role in the evasion of tumor immunity. J. Mol. Med. 2003. 81: 281-287.
33. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T. and Minato, N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 2002. 99: 12293-12297.
34. Carter, L., Fouser, L. A., Jussif, J., Fitz, L., Deng, B., Wood, C. R., Collins, M. et al., PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur. J. Immunol. 2002. 32: 634-643.
35. Dunn, G. P., Old, L. J. and Schreiber, R. D., The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004. 22: 329-360.
36. + T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 2006. 24: 5060-5069.
37. Meidenbauer, N., Zippelius, A., Pittet, M. J., Laumer, M., Vogl, S., Heymann, J., Rehli, M. et al., High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res. 2004. 64: 6319-6326.
38. Nishimura, H., Minato, N., Nakano, T. and Honjo, T., Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 1998. 10: 1563-1572.
39. Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E. et al., A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 1995. 92: 9363-9367.